05:35 PM EDT, 04/10/2024 (MT Newswires) -- Pharvaris ( PHVS ) late Wednesday reported a Q4 net loss of 0.74 euros ($0.80) per diluted share, compared with a 1.16 euro loss a year earlier.

Analysts polled by Capital IQ expected a 0.57 loss.

As expected, the biopharmaceuticals company did not report any revenue during the quarter ended Dec. 31 or a year earlier.

It finished 2023 with 391 million euros in cash and cash equivalents, compared with around 162 million euros at the end of 2022.

The company also disclosed the hiring of David Nassif as chief financial officer, starting from April 15. Nassif is the chief executive, CFO and board member at Sio Gene Therapies.

Price: 22.28, Change: +0.01, Percent Change: +0.04